Isryl 1 Tablet contains Glimepiride 1 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. Glimepiride acts by stimulating insulin release from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. It is primarily prescribed as an adjunct to diet and exercise when these measures alone are insufficient to achieve adequate blood glucose levels. Isryl 1 Tablet is typically initiated at a low dose and titrated based on the patient’s glycemic response and tolerance. The medication should be taken orally once daily with breakfast or the first main meal to reduce the risk of hypoglycemia. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Patient education on recognizing and managing hypoglycemia is essential to ensure safe and effective use of Isryl 1 Tablet in diabetes management.